DRUG · Bright Minds Biosciences Inc.

Bright Minds Biosciences' second quarter fiscal 2026 results reflect a significant inflection point as the company transitions from early-stage research to active clinical development. The net loss for the six-month period widened to $18.0 million from $2.9 million in the prior year, primarily due to a fivefold increase in R&D expenses to $18.7 million. The surge in R&D spending is attributable to the advancement of lead candidate BMB-101 into Phase 2 studies for drug-resistant epilepsies and developmental epileptic encephalopathies (DEE), as well as the initiation of a Prader-Willi syndrome program. The company reported positive topline Phase 2 results for BMB-101 in January 2026, demonstrating substantial seizure reductions and a favorable safety profile. Preparations for global registrational trials are underway. The balance sheet was dramatically strengthened through a public offering in January 2026 that raised approximately $243 million in net proceeds, increasing cash to $309.7 million. This provides the company with a robust runway to fund operations and clinical milestones for at least 12 months. Interest income of $3.5 million partially offset operating losses. The company has not yet generated revenue and remains dependent on successful development and regulatory approval. Investors should monitor upcoming data from the Phase 2/3 programs and potential partnership opportunities.